Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
Launched by EVOFEM INC. · Mar 24, 2015
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy male or non-pregnant female subjects
- • Capable of providing written consent.
- • BMI \< 30 kg/m2
- • Stable diet and exercise routine
- • Central abdominal bulging that is evaluated by the clinician at least slight bulge, not flat
- Exclusion Criteria:
- • Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen.
- • Plan on starting a weight loss or exercise program during the study.
- • Known hypersensitivity to study drugs
About Evofem Inc.
Evofem Inc. is a clinical-stage biopharmaceutical company dedicated to advancing women's health through the development of innovative contraceptive and sexually transmitted infection prevention solutions. With a focus on addressing unmet medical needs, Evofem is committed to pioneering research that empowers women with safe and effective options. The company's lead product, Phexxi™, represents a groundbreaking approach to contraception, utilizing a non-hormonal mechanism designed to offer women greater control over their reproductive health. Through rigorous clinical trials and a commitment to scientific excellence, Evofem aims to enhance the quality of life for women worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
South Bend, Indiana, United States
Raleigh, North Carolina, United States
Denver, Colorado, United States
Birmingham, Alabama, United States
Nashville, Tennessee, United States
Portland, Oregon, United States
South Miami, Florida, United States
Tampa, Florida, United States
New Haven, Connecticut, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Austin, Texas, United States
Lake Worth, Florida, United States
Chestnut Hill, Massachusetts, United States
Chicago, Illinois, United States
Montclair, New Jersey, United States
New York, New York, United States
Oceanside, California, United States
Dallas, Texas, United States
Encinitas, California, United States
Spokane, Washington, United States
Miami, Florida, United States
Washington, Missouri, United States
Santa Ana, California, United States
Carmel, Indiana, United States
Beverly Hills, California, United States
Manhattan Beach, California, United States
Rancho Mirage, California, United States
San Diego, California, United States
San Diego, California, United States
Miami, Florida, United States
Edina, Minnesota, United States
Chadds Ford, Pennsylvania, United States
Houston, Texas, United States
Pflugerville, Texas, United States
Patients applied
Trial Officials
Maria Feldman
Study Director
Neothetics, Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials